Translational Drug Development (TD2)
Translational Drug Development (TD2) is an oncology CRO dedicated to precision medicine. We work with innovative biotech and pharma companies to bring cancer treatments to patients as quickly as possible.
Our clients have exclusive access to an integrated suite of tools that support every research milestone, and efficiently—from preclinical process to regulatory strategy, clinical support and an expansive patient database that makes recruiting easier than ever.
Born from the Translational Genomics Research Institute (TGen), TD2 was formed in 2003 as a subsidiary of TGen, and less than two years later, opened its doors on the campus of the Mayo Clinic in Scottsdale, Ariz. In our 15 years of business, we have helped more than 600 biotech and pharma companies, maintaining hundreds of client studies per year. Among them, our team has been involved in more than 600 first-in-man major oncology medicines, including numerous trials that have led to approvals in both rare and large indications.